New results show that our gut microbiome affects treatment outcomes of anti-helminthic drugs.
New results show that our gut microbiome affects treatment outcomes of anti-helminthic drugs. Almost a quarter of the world's population is at risk of helminth infections and available treatment options are limited. Therefore, a better understanding of why anti-parasitic drugs fail in certain cases is crucial. A new study by Swiss TPH sheds light on how gut bacteria affect treatment outcomes against parasitic worms. The findings were published today in the journal Nature Communications. 1.5 billion people worldwide, particularly in lowand middle-income countries (LMICs), are infected with soil-transmitted helminths (STHs). These parasitic worm infections cause a myriad of symptoms from diarrhoea to poor cognitive development.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
